Evidence map›Paper›PMID 41399410›Full record

ArticleJournal of pharmaceutical analysis2025

Obtain substance of anti-glioblastoma from Erigeron breviscapus through fragment-based target research (FBTR): An efficient strategy for pharmacology investigation and optimization of natural products.

Chunguo Wang, Jinli Shi, Qinling Rao, Bingqing Shen, Canyu Su, Heng Chen, Zhixing Huang, Shuwei Jiang, Rongge He, Luni Xu and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chunguo WangBeijing University of Chinese Medicine, Beijing, 102488, China.
Jinli ShiBeijing University of Chinese Medicine, Beijing, 102488, China.
Qinling RaoBeijing University of Chinese Medicine, Beijing, 102488, China.
Bingqing ShenBeijing University of Chinese Medicine, Beijing, 102488, China.
Canyu SuBeijing University of Chinese Medicine, Beijing, 102488, China.
Heng ChenBeijing University of Chinese Medicine, Beijing, 102488, China.
Zhixing HuangBeijing University of Chinese Medicine, Beijing, 102488, China.
Shuwei JiangBeijing University of Chinese Medicine, Beijing, 102488, China.
Rongge HeBeijing University of Chinese Medicine, Beijing, 102488, China.
Luni XuBeijing University of Chinese Medicine, Beijing, 102488, China.
Muxuan LiBeijing University of Chinese Medicine, Beijing, 102488, China.
Yonggang LiuBeijing University of Chinese Medicine, Beijing, 102488, China.
Tao MaBeijing University of Chinese Medicine, Beijing, 102488, China.
Yantong XuBeijing University of Chinese Medicine, Beijing, 102488, China.
Xinqi DengInstitute of Chinese Materia Medica China Academy of Chinese Medical Sciences, Beijing, 100700, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural products (NPs) make a major contribution to drug development, offering a huge molecule pool for drug leads. Nevertheless, the pharmaceutical industry and academy have declined their enthusiasm to NPs research since the great challenges in elucidating the complex component and intricate mechanism of NPs. Here, we introduce an efficient fragment-based target research (FBTR) approach for pharmacology study and optimization of NPs. Focusing on the core fragment within the molecules of NPs, we screen the outstanding activity that be triggered, and corresponding target. Finally, drug optimization was carried out around the molecules that obtaining the activity-related core fragment and verified both

Indexed as

Drug optimizationFragment-basedNatural productTarget

Identifiers

PMID41399410
PMCPMC12701987

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.